|

Drug-Drug Interaction Study of ABP-671 in Gout Patients

RECRUITINGPhase 1Sponsored by Atom Therapeutics Co., Ltd
Actively Recruiting
PhasePhase 1
SponsorAtom Therapeutics Co., Ltd
Started2026-01-23
Est. completion2026-07-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07367971

Summary

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adults 18-75 years with clinical diagnosis of gout.
* Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
* Cohort N: Normal renal function.
* Cohort R: Moderate renal impairment.

Exclusion Criteria:

* Clinically significant hepatic impairment.
* History of Allopurinol hypersensitivity.
* Pregnancy or breastfeeding.

Conditions4

ArthritisDDI (Drug-Drug Interaction)GoutGout Chronic

Interventions1

ABP-671 plus allopurinol

Locations1 site

Wakefield Clinical Research
Cary, North Carolina, 27560
Xiaohuan Li, MD

Find trials near these locations

All trials in North Carolina

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.